Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

McKesson (MCK)

NYSE: MCK · Medical Distribution · Irving, TX

Our rating: Positive

Positive reaffirmed at $1072.00, moderate conviction, November 5, 2026.

Breaks if: The positive case breaks if revenue growth falls below 7% year-over-year in either of the next two quarterly filings — the clearest signal that pharmaceutical volume tailwinds are fading and that prior growth was more price-inflation than volume — or if trailing-twelve-month free cash flow drops below $4.5B, suggesting cash conversion has deteriorated. Either condition, observed within the next twelve months, would prompt a step down to Neutral or below.

Key figures

Market value$123.5B
Revenue, last 12 months$418.8B
Net income, last 12 months$4.7B
Free cash flow, last 12 months$7.1B
Price to earnings26.3×
Free cash flow yield5.8%
Dividend yield0.3%
Operating margin1.6%
Return on equityn/a
Beta to the S&P 5000.03
Volatility, annualized28.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$111.0B7.6%$10.44$3.0B
June 30, 2026$105.4B7.7%$5.15−$332M
March 31, 2026$96.3B6.0%$13.65$3.3B
December 31, 2025$106.2B11.4%$9.59$1.1B
September 30, 2025$103.2B10.1%$8.92$2.3B
June 30, 2025$97.8B23.4%$6.25−$1.0B
March 31, 2025$90.8B18.9%$9.92$7.6B
December 31, 2024$95.3B17.8%$6.95−$2.5B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 50 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.